The arrival of Donald Trump as US president-elect has set the talking heads across the business media into over drive with predictions and analysis as to what President Trump may mean for the ASX and equity markets.

In the interests of brevity and clarity I’ve summarised below what I think investors should expect in the years ahead due to the Trump effect.

  • Tax cuts
  • Construction
  • Healthcare reform
  • Stronger U.S. dollar

I won’t follow some pundits in suggesting the U.S. dollar is set to rocket under Trump’s fiscal loosening, but I think it a sensible expectation that it could appreciate around 10% over the Australian dollar during the course of 2017.

This would take the Australian dollar to a level where it buys around 68-70 U.S. cents and will support ASX companies with substantial U.S dollar earnings. Below I have five to consider for forward-thinking investors.

Sirtex Medical Limited (ASX: SRX) is the liver cancer treatment business that is growing at double-digit rates mainly thanks to the strength of sales in its core U.S. market. Shares sell for $28.05, which looks good value, especially when you consider the potential kick ahead when the company releases the results of several clinical trials over 2017.

Magellan Financial Group Ltd (ASX: MFG) is the international equities manager that is a big beneficiary of a stronger U.S. dollar and equity markets in 2017. Moreover, it continues to deliver strong retail and institutional inflows and I expect it will reveal a big jump in total funds under management in early December. At $21.85 with a trailing 4% yield the shares look good value to me.

ResMed Inc. (CHESS) (ASX: RMD) offers investors direct exposure to a stronger U.S. dollar and continues to deliver consistent growth in revenues and earnings. Its margins have also been under pressure due to recent U.S. healthcare reforms that may be reversed under a Republican government in North America. The stock also looks decent value at $7.85.

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) also operates in the sleep apnea space with a lot of U.S. dollar earnings thanks to the success of its operations in the world’s largest healthcare market. Much of its foreign currency exposure is hedged, however, with the underlying business producing some exceptional growth it’s a business to watch.

Nanosonics Ltd (ASX: NAN) is the hospital disinfectant equipment business that is growing sales strongly to public and private hospitals in the North America. In financial year 2016 it more than doubled sales to U.S. hospitals with momentum reportedly carrying on into the new financial year. It ticks the boxes as an exciting growth prospect, although with shares selling for $3.19 on a market value close to $1 billion it seems like there are some great expectations already factored into the price.

Importantly, all of these businesses have the potential to perform well over the long term irrespective of who occupies the White House or what direction the U.S. dollar takes in the years ahead. However, if Trump’s fiscal policies boost inflation and lead to a higher U.S. dollar they may do especially well.

Discover How 1 Man Made 100x His Money After 50

Few know, that as Warren Buffett blew out the candles on his 50th birthday cake, he had just 1% of his current fortune. Think about it: At an age when most give up hope, Buffett was just getting started on the remaining 99% of his fortune. Goes to show you that it's never too late for you to potentially get rich. Which is why we've gathered the strategies we learned from Buffett, distilled them down to 11 simple lessons, and put it in an exclusive report for you to claim. Just click here to learn more about this handy investing guide.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Tom Richardson owns shares of Magellan Financial Group, ResMed Inc., and Sirtex Medical Limited. The Motley Fool Australia owns shares of Nanosonics Limited.

 

You can find Tom on Twitter @tommyr345

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.